Agilent Technologies, Inc. Expected to Earn Q3 2024 Earnings of $1.27 Per Share (NYSE:A)

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Zacks Research lowered their Q3 2024 earnings estimates for Agilent Technologies in a research report issued on Wednesday, June 19th. Zacks Research analyst S. Mete now forecasts that the medical research company will post earnings per share of $1.27 for the quarter, down from their previous forecast of $1.44. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.25 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2024 earnings at $1.45 EPS, FY2024 earnings at $5.23 EPS, Q1 2025 earnings at $1.40 EPS, Q2 2025 earnings at $1.36 EPS, Q3 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.56 EPS, FY2025 earnings at $5.71 EPS and Q1 2026 earnings at $1.59 EPS.

Several other equities analysts have also issued reports on the company. Bank of America reissued a “neutral” rating and set a $134.00 target price (down previously from $145.00) on shares of Agilent Technologies in a research note on Thursday, May 30th. Jefferies Financial Group reissued a “hold” rating and issued a $135.00 price objective (down previously from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. UBS Group dropped their price objective on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a report on Thursday, May 30th. Citigroup reduced their target price on shares of Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating on the stock in a report on Thursday, May 30th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.50.

Agilent Technologies Trading Up 0.4 %

A opened at $133.26 on Friday. Agilent Technologies has a 52 week low of $96.80 and a 52 week high of $155.35. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. The business has a fifty day simple moving average of $139.83 and a 200-day simple moving average of $138.25. The firm has a market cap of $38.88 billion, a P/E ratio of 31.50, a P/E/G ratio of 4.57 and a beta of 1.07.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.03. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The firm’s quarterly revenue was down 8.4% on a year-over-year basis. During the same quarter last year, the company posted $1.27 EPS.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Tuesday, July 2nd. Agilent Technologies’s payout ratio is 22.22%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the sale, the senior vice president now owns 49,486 shares in the company, valued at $6,595,494.08. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the sale, the chief executive officer now owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,785 shares of company stock worth $2,670,836.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Agilent Technologies by 18.2% during the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after purchasing an additional 4,605,228 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Agilent Technologies by 19.6% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock valued at $1,841,659,000 after acquiring an additional 2,170,219 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Agilent Technologies by 17.4% during the third quarter. Wellington Management Group LLP now owns 10,255,526 shares of the medical research company’s stock worth $1,146,773,000 after acquiring an additional 1,519,134 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Agilent Technologies by 6.6% in the 3rd quarter. Northern Trust Corp now owns 4,097,313 shares of the medical research company’s stock valued at $458,162,000 after purchasing an additional 254,998 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.